SightfileU.S. market data from official filings

Companies › BVS

BIOVENTUS (BVS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001665988 · EDGAR filings · Updated 2026-07-27

BIOVENTUS (BVS) has reported institutional ownership of 75.9%, with 157 institutional managers holding positions valued at $466.4M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
75.9%
Institutional managers
157
Reported 13F value
$466.4M
Insider activity
41 trans.
−$374.0K net selling
Data flags
1 active
from SEC filings

Filings this week (1)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BIOVENTUS has 157 institutional holders and institutional ownership of 75.9%.

Insider activity

Insiders reported 41 transactions (0 buys, 6 sells) across 15 reporting insiders, with a net reported value of −$374.0K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2024-03-12 (recurring since 2022-11-21) — source filing. The authoritative details are those stated in the filing itself.

Related companies

MINIMED GROUP INC (MMED) · SANA BIOTECHNOLOGY INC (SANA) · 4D MOLECULAR THERAPEUTICS IN (FDMT) · AVALO THERAPEUTICS INC (AVTX) · CRESCENT BIOPHARMA INC. (CBIO) · LEXEO THERAPEUTICS INC (LXEO)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-27.